Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Lipoprotein(a) is a significant causal risk factor for cardiovascular disease (CVD) and mortality.
• Current therapeutic options for effectively reducing Lipoprotein(a) are limited.
• Global guidelines now recommend universal, one-time Lipoprotein(a) screening.

Purpose of the Study:

• To review recent findings on Lipoprotein(a) as a CVD risk factor and therapeutic target.
• To discuss current clinical recommendations for managing Lipoprotein(a).
• To summarize emerging Lipoprotein(a)-lowering drugs.

Main Methods:

• Review of epidemiological and genetic studies establishing Lipoprotein(a) causality.
• Analysis of clinical trial data for novel therapeutic agents.
• Synthesis of current international clinical guidelines.

Main Results:

• Established Lipoprotein(a) as a causal risk factor for CVD.
• Demonstrated significant Lipoprotein(a) reduction (up to 106%) with novel therapies (ASOs, siRNAs, oral inhibitors) in Phase 1/2 trials.
• Observed no major adverse effects associated with these new treatments.

Conclusions:

• Lipoprotein(a) is a validated therapeutic target for CVD risk reduction.
• Emerging pharmacological interventions show high efficacy and safety in lowering Lipoprotein(a).
• Ongoing Phase 3 trials are expected to lead to new treatments for managing Lipoprotein(a)-associated cardiovascular risk.